WallStSmart
BOLD

Boundless Bio, Inc. Common Stock

NASDAQ: BOLD · HEALTHCARE · BIOTECHNOLOGY

$1.50
-3.40% today

Updated 2026-06-05

Market cap
$57.53M
P/E ratio
P/S ratio
EPS (TTM)
$-2.49
Dividend yield
52W range
$1 – $3
Volume
1.5M

WallStSmart proprietary scores

29
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
5.0
Quality
C+
3.0
Profitability
D
5.0
Valuation
C+
1/9
Piotroski F-Score
Weak
-1.8
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →204 stocks currently score above 75

Price targets

Analyst target
$4.00
+166.67%
12-Month target
Intrinsic (DCF)
Margin of safety
0 Strong Buy0 Buy2 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -1.78 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-14.98M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$0.00$0.00
Net income$-45.90M$-49.43M$-65.36M$-58.20M$-13.55M
EPS$-2.49
Free cash flow$-40.66M$-47.49M$-63.38M$-47.21M$-14.98M
Profit margin

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
BOLD$57.53M294.33.05.05.0Avoid
LLY$1.08T7810.010.05.06.0Strong Buy
JNJ$613.02B574.79.03.36.0-87.08%Buy
ABBV$447.62B634.08.04.75.0-73.27%Buy
UNH$388.59B545.35.54.05.5-33.19%Buy
NVS$296.54B493.39.03.34.5-69.70%Hold

Smart narrative

Boundless Bio, Inc. Common Stock trades at $1.50. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -1.78, it sits in the distress.

Frequently asked questions

What is Boundless Bio, Inc. Common Stock's stock price?

Boundless Bio, Inc. Common Stock (BOLD) trades at $1.50.

Is Boundless Bio, Inc. Common Stock overvalued?

Boundless Bio, Inc. Common Stock carries a Smart Value Score of 29/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Boundless Bio, Inc. Common Stock (BOLD)?

The 12-month analyst consensus target is $4.00, about 166.7% above the current $1.50. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Boundless Bio, Inc. Common Stock's Altman Z-Score is -1.78, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio
ROE-64.82%
Beta0.97
50D MA$1.56
200D MA$1.29
Shares out0.02B
Float0.02B
Short ratio
Avg volume1.5M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years